JP7618950B2 - 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 - Google Patents
免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 Download PDFInfo
- Publication number
- JP7618950B2 JP7618950B2 JP2021516357A JP2021516357A JP7618950B2 JP 7618950 B2 JP7618950 B2 JP 7618950B2 JP 2021516357 A JP2021516357 A JP 2021516357A JP 2021516357 A JP2021516357 A JP 2021516357A JP 7618950 B2 JP7618950 B2 JP 7618950B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tumor
- cells
- toxin
- analogue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024223694A JP2025038162A (ja) | 2018-09-19 | 2024-12-19 | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306219 | 2018-09-19 | ||
| EP18306219.9 | 2018-09-19 | ||
| PCT/EP2019/075080 WO2020058372A1 (en) | 2018-09-19 | 2019-09-18 | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024223694A Division JP2025038162A (ja) | 2018-09-19 | 2024-12-19 | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022511337A JP2022511337A (ja) | 2022-01-31 |
| JP2022511337A5 JP2022511337A5 (cg-RX-API-DMAC7.html) | 2022-09-07 |
| JP7618950B2 true JP7618950B2 (ja) | 2025-01-22 |
Family
ID=63787877
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021516357A Active JP7618950B2 (ja) | 2018-09-19 | 2019-09-18 | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 |
| JP2024223694A Pending JP2025038162A (ja) | 2018-09-19 | 2024-12-19 | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024223694A Pending JP2025038162A (ja) | 2018-09-19 | 2024-12-19 | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220073638A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3853251A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7618950B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113396160A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020058372A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025038162A (ja) * | 2018-09-19 | 2025-03-18 | インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11634501B2 (en) | 2019-07-19 | 2023-04-25 | Oncoresponse, Inc. | Immunomodulatory antibodies and methods of use thereof |
| US20220363776A1 (en) * | 2019-10-04 | 2022-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
| CA3233490A1 (en) * | 2021-09-28 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for t cell targeted delivery of therapeutic agents |
| CN114694745A (zh) * | 2022-03-24 | 2022-07-01 | 至本医疗科技(上海)有限公司 | 预测免疫疗效的方法、装置、计算机设备和存储介质 |
| WO2024015560A1 (en) * | 2022-07-15 | 2024-01-18 | Whitehead Institute For Biomedical Research | Combination of macrophage-directed immunotherapy and cytokines for treatment of cancer |
| JP2026519901A (ja) | 2023-01-27 | 2026-06-19 | ヴィーアイビー ヴィーゼットヴィー | Cd163結合複合体 |
| EP4563596A1 (en) * | 2023-11-30 | 2025-06-04 | OncoSpear ApS | Anti-cd163 antibodies with improved adcc capabilities |
| AU2024391672A1 (en) | 2023-11-30 | 2026-05-21 | Oncospear Aps | Anti-cd163 antibodies with improved adcc capabilities |
| WO2025207936A1 (en) * | 2024-03-28 | 2025-10-02 | Mirror Biologics, Inc. | Treatment for colorectal cancer using immune checkpoint inhibitors |
| CN120695211A (zh) * | 2025-06-25 | 2025-09-26 | 广东医科大学附属医院 | mRNA组合物及其在制备肝纤维化治疗药物中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017533912A (ja) | 2014-10-29 | 2017-11-16 | ファイヴ プライム セラピューティクス インク | がんのための併用療法 |
| WO2018156725A1 (en) | 2017-02-24 | 2018-08-30 | Thomas Jefferson University | Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors |
| WO2018158658A1 (en) | 2017-03-03 | 2018-09-07 | Rinat Neuroscience Corp. | Anti-gitr antibodies and methods of use thereof |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| KR100944575B1 (ko) | 2002-10-17 | 2010-02-25 | 젠맵 에이/에스 | Cd20에 대한 인간 모노클로날 항체 |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| GB0229734D0 (en) | 2002-12-23 | 2003-01-29 | Qinetiq Ltd | Grading oestrogen and progesterone receptors expression |
| US7257268B2 (en) | 2003-02-28 | 2007-08-14 | Aperio Technologies, Inc. | Systems and methods for image pattern recognition |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| US7837980B2 (en) | 2004-03-02 | 2010-11-23 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| JP2008519863A (ja) | 2004-11-12 | 2008-06-12 | シアトル ジェネティクス インコーポレイティッド | N末端にアミノ安息香酸単位を有するオーリスタチン |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EP1898529A1 (en) | 2005-06-28 | 2008-03-12 | Pioneer Corporation | Broadcast receiving apparatus, interference detecting apparatus and interference detecting method |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| HUE035853T2 (en) | 2005-07-18 | 2018-05-28 | Seattle Genetics Inc | Beta-glucuronide-linker-drug conjugates |
| US8023714B2 (en) | 2007-06-06 | 2011-09-20 | Aperio Technologies, Inc. | System and method for assessing image interpretability in anatomic pathology |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| CN102165489B (zh) | 2008-09-16 | 2015-11-25 | 赫斯托克斯公司 | 生物标志物表达的可再现量化 |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
| US8345509B2 (en) | 2009-04-16 | 2013-01-01 | Chevron U.S.A., Inc. | System and method to create three-dimensional images of non-linear acoustic properties in a region remote from a borehole |
| GB0917044D0 (en) * | 2009-09-29 | 2009-11-18 | Cytoguide As | Agents, uses and methods |
| US20110111435A1 (en) | 2009-11-06 | 2011-05-12 | SlidePath Limited | Detecting Cell Surface Markers |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| HUE039339T2 (hu) | 2013-03-15 | 2018-12-28 | Bristol Myers Squibb Co | Indolamin-2,3-dioxigenáz (IDO) inhibitorai |
| RS57508B1 (sr) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Tech Ltd | 1,2,4-derivati oksadiazola kao imunomodulatori |
| TR201811077T4 (tr) | 2013-09-06 | 2018-08-27 | Aurigene Discovery Tech Ltd | İmmünomodülatörler olarak 1,3,4-oksadiazol ve 1,3,4-tiyadiyazol türevleri. |
| CR20180243A (es) | 2015-10-02 | 2018-07-31 | Genentech Inc | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso |
| US10617672B2 (en) * | 2015-10-15 | 2020-04-14 | Lipomedix Pharmaceuticals Ltd. | Liposome composition co-encapsulating doxorubicin and a prodrug of mitomycin C |
| CN108495651A (zh) * | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| ITUB20160191A1 (it) * | 2016-01-21 | 2017-07-21 | Invectors S R L | Kit per la preparazione di doxorubicina liposomiale funzionalizzata con peptidi per il target selettivo di recettori sovra espressi da cellule tumorali |
| CA3028589A1 (en) * | 2016-06-21 | 2017-12-28 | Therapure Biopharma Inc. | Hemoglobin-targeted drug delivery for the treatment of cancer |
| EP3491387A1 (en) * | 2016-07-28 | 2019-06-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods of treatement of cancer disease by targetting tumor associated macrophage |
| EP3504239B1 (en) * | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| IL317919A (en) * | 2016-12-05 | 2025-02-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| WO2020058372A1 (en) * | 2018-09-19 | 2020-03-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy |
-
2019
- 2019-09-18 WO PCT/EP2019/075080 patent/WO2020058372A1/en not_active Ceased
- 2019-09-18 EP EP19768864.1A patent/EP3853251A1/en active Pending
- 2019-09-18 US US17/276,432 patent/US20220073638A1/en active Pending
- 2019-09-18 JP JP2021516357A patent/JP7618950B2/ja active Active
- 2019-09-18 CN CN201980062859.6A patent/CN113396160A/zh active Pending
-
2024
- 2024-12-19 JP JP2024223694A patent/JP2025038162A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017533912A (ja) | 2014-10-29 | 2017-11-16 | ファイヴ プライム セラピューティクス インク | がんのための併用療法 |
| WO2018156725A1 (en) | 2017-02-24 | 2018-08-30 | Thomas Jefferson University | Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors |
| WO2018158658A1 (en) | 2017-03-03 | 2018-09-07 | Rinat Neuroscience Corp. | Anti-gitr antibodies and methods of use thereof |
Non-Patent Citations (2)
| Title |
|---|
| Jonas Heilskov Graversen, Soren Kragh Moestrup,Drug Trafficking into Macrophages via the Endocytotic Receptor CD163,Membranes, Vol. 5,228-252,https://www.mdpi.com/2077-0375/5/2/228 |
| Journal of Controlled Release,2012年,Vol.160,pp.72-80 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025038162A (ja) * | 2018-09-19 | 2025-03-18 | インサーム (インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシェ メディカル) | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3853251A1 (en) | 2021-07-28 |
| JP2025038162A (ja) | 2025-03-18 |
| WO2020058372A1 (en) | 2020-03-26 |
| CN113396160A (zh) | 2021-09-14 |
| JP2022511337A (ja) | 2022-01-31 |
| US20220073638A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025038162A (ja) | 免疫チェックポイント治療に抵抗性のある癌の治療のための方法および医薬組成物 | |
| JP7153626B2 (ja) | 抗ヒト4-1bb抗体およびその使用 | |
| JP7129449B2 (ja) | ヒト化ccケモカイン受容体4(ccr4)抗体およびその使用法 | |
| KR102291971B1 (ko) | 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도 | |
| KR20180081606A (ko) | 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제 | |
| CA2851762A1 (en) | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) | |
| US20090299038A1 (en) | Anti-hdlk-1 antibody having an antitumor activity in vivo | |
| AU2007318483A1 (en) | Anti-human Dlk-1 antibody showing anti-tumor activity in vivo | |
| US20240175873A1 (en) | Methods for the diagnosis and treatment of t cell-lymphomas | |
| CN113544151A (zh) | 抗il-27抗体及其用途 | |
| CN108474793A (zh) | 预后方法 | |
| WO2019089753A2 (en) | Cd137 antibodies and pd-1 antagonists and uses thereof | |
| TW202116807A (zh) | 用於治療特定患者之癌症的抗體組合 | |
| TW202340243A (zh) | 抗cd39抗體及其用途 | |
| JP6159010B2 (ja) | テトラスパニン8に対するハイブリドーマクローンおよびモノクローナル抗体 | |
| JP6159011B2 (ja) | Cd9に対するハイブリドーマクローンおよびモノクローナル抗体 | |
| KR102487356B1 (ko) | 종양 관련 대식세포를 표적화하는 항체 및 이의 용도 | |
| WO2019199896A1 (en) | Agonist antibodies against human cd137 in cancer that express mhc i | |
| WO2024003310A1 (en) | Methods for the diagnosis and treatment of acute lymphoblastic leukemia | |
| JP2020507576A (ja) | Mapk経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物 | |
| JP2023525053A (ja) | 皮膚t細胞リンパ腫及びtfh由来リンパ腫を処置する新しい方法 | |
| CN117177771A (zh) | 一种诊断和治疗t细胞淋巴瘤的方法 | |
| EP4508432A1 (en) | Methods for the diagnosis and treatment of t-cell malignancies | |
| WO2023198874A1 (en) | Methods for the diagnosis and treatment of t cell-lymphomas | |
| WO2024023283A1 (en) | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210518 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220830 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220830 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230906 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231205 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240305 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240531 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240802 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241119 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241219 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7618950 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |